Segment, Geographic and Other Revenue Information - Schedule of Segment Reporting Information by Segment (Details) - USD ($) $ in Millions		3 Months Ended
		Apr. 02, 2023	Apr. 03, 2022
Segment Reporting Information [Line Items]
Revenues		$ 18,282	$ 25,661
Income from continuing operations before provision/(benefit) for taxes on income	[1]	6,270	9,050
Net gains/(losses) recognized during the period on equity securities	[2],[3]	(451)	(699)
ViiV [Member]
Segment Reporting Information [Line Items]
Dividend income		92	56
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	[4]	310	338
Income from continuing operations before provision/(benefit) for taxes on income	[1],[4]	(2,734)	(2,429)
Other Business Activities [Member] | Reclassification Adjustment [Member]
Segment Reporting Information [Line Items]
Operating costs			(47)
Reconciling Items [Member] | Amortization of Intangible Assets [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income	[1]	(1,103)	(835)
Reconciling Items [Member] | Acquisition-Related Items [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income	[1]	(163)	(187)
Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Income from continuing operations before provision/(benefit) for taxes on income	[1],[5]	(665)	(891)
Net gains/(losses) recognized during the period on equity securities		(452)	(698)
Biopharma [Member]
Segment Reporting Information [Line Items]
Revenues	[6]	17,971	25,323
Biopharma [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		17,971	25,323
Income from continuing operations before provision/(benefit) for taxes on income	[1]	$ 10,936	13,391
Biopharma [Member] | Operating Segments [Member] | Reclassification Adjustment [Member]
Segment Reporting Information [Line Items]
Operating costs			$ 47

[1] Income from continuing operations before provision/(benefit) for taxes on income. Biopharma’s earnings include dividend income from our investment in ViiV of $92 million in the first quarter of 2023 and $56 million in the first quarter of 2022. In connection with the organizational changes effective in the third quarter of 2022, certain functions transferred between Biopharma and corporate enabling functions and certain activities were realigned within the GPD organization. We have reclassified $47 million of costs in the first quarter of 2022 from corporate enabling functions, which are included in Other business activities, to Biopharma to conform to the current period presentation.

[2] Reported in Other (income)/deductions––net. See Note 4.

[3] The losses in the first quarter of 2023 include, among other things, unrealized losses of $363 million related to our investments in Cerevel Therapeutics Holdings, Inc. and BioNTech. The losses in the first quarter of 2022 included, among other things, unrealized losses of $473 million related to our investment in BioNTech.

[4] Other business activities include revenues and costs associated with Business Innovation and costs that we do not allocate to our operating segments, per above, including acquired IPR&D expenses in the periods presented.

[5] Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above). Earnings in the first quarter of 2023 and 2022 include, among other items, net losses on equity securities of $452 million and $698 million, respectively, recorded in Other (income)/deductions––net. See Note 4.

[6] See Note 1A in our 2022 Form 10-K for information about our recent organizational changes within Biopharma. See Note 13A above for information about Business Innovation. Prior-period financial information has been revised to reflect the current period presentation.